88344
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 14
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -4.394695698
- umap2_2d
- 1.407487777
- umap1_3d
- 0.027201063
- umap2_3d
- 2.3984734
- umap3_3d
- -1.535401615
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.410
- E2F_TARGETS+0.400
- INTERFERON_GAMMA_RESPONSE+0.260
- APOPTOSIS+0.250
- INFLAMMATORY_RESPONSE+0.250
- ALLOGRAFT_REJECTION+0.200
- KRAS_SIGNALING_DN+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.190
- INTERFERON_ALPHA_RESPONSE+0.180
- UNFOLDED_PROTEIN_RESPONSE+0.180
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.320
- DNA_REPAIR-0.310
- NOTCH_SIGNALING-0.260
- MYC_TARGETS_V2-0.250
- HYPOXIA-0.210
- PEROXISOME-0.210
- MYOGENESIS-0.180
- ADIPOGENESIS-0.120
- HEME_METABOLISM-0.120
- FATTY_ACID_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278857 | — | — | 0.708 |
| 2 | s0122319 | — | — | 0.692 |
| 3 | TCGA-21-1070-01A-01R-0692-07 | — | cohortSQ1 | 0.683 |
| 4 | DRR168533 | — | — | 0.682 |
| 5 | 8828489a-e6fd-43ca-9232-e1b759d6edcf | — | — | 0.675 |
| 6 | SRR4296088 | — | cohortMD2 | 0.670 |
| 7 | MNG751 | — | — | 0.669 |
| 8 | a45a7511-4aa9-4d04-8f5f-34d12e4d5917 | — | — | 0.654 |
| 9 | MNG539 | — | — | 0.652 |
| 10 | 20ca78ce-1972-4f55-81f2-22683da33c66 | — | — | 0.652 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |